1. Scrip
  2. >>Business
  3. >>Strategy

Cloud Pharmaceuticals' Don Van Dyke On Applying Cloud Computing To Drug Discovery

 
• By Joseph Haas

Biotech uses cloud computing and artificial intelligence to accelerate the discovery and design of small-molecule drug candidates across a broad range of therapeutic areas.

Boston – Cloud Pharmaceuticals Inc. Chief Operating Officer Don Van Dyke spoke with Scrip at BioPharm America 2016 about how the company uses cloud computing to accelerate the discovery and design of novel small-molecule drug candidates in therapeutic areas such as cancer, inflammatory disease, infectious disease and central nervous system disorders.

Van Dyke discussed how an ongoing partnership helped Cloud develop its technology for creating drug candidates that can pervade the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By Kevin Grogan

Comes Days After PDUFA Pushback For GSK's Blenrep.

Dr Reddy’s On Semaglutide Prospects, Capacity And There’s An IP Hearing To Watch

 
• By Anju Ghangurde

Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 
• By Jessica Merrill

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 
• By Joseph Haas, Lisa Takagi, and Manas Mishra

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Sanofi’s Vicebio buy; Sarepta halts US Elevidys shipments; Novartis warning over Europe; US CRL for Genentech’s Columvi; and an interview with Novavax.

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 
• By Jessica Merrill

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.